Eligible patients received bevacizumab ( 15 mg/kg ) , trastuzumab ( 8 mg/kg loading dose followed by 6 mg/kg ) , and docetaxel ( 100 mg/m2 initially , later amended to 75 mg/m2 ) every three weeks for six cycles and then were allowed to receive bevacizumab and trastuzumab alone .